BioCryst Pharmaceuticals Inc
BCRXStock
$9.11+7.91%52W
Market Cap$2.33B
P/E8.82x
Div yield—
Beta0.57
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)9.35%
Price vs S&P 500 (4W)4.90%
VGM Score63.23
Market Capitalization$2.33B
P/E Ratio (Annual)8.82x
Earnings Surprise History
Q1 26-0.09est. 0.05
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.25
4.25
4.25
4.25
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BCRXBioCryst Pharmaceuticals Inc | B | B | C | $9.11 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
BioCryst Pharmaceuticals is a biotechnology company developing small-molecule drugs that target key enzymes involved in infectious and inflammatory diseases. The company's clinical and preclinical pipeline addresses acute and seasonal influenza, hereditary angioedema, filoviruses including Ebola and Marburg, and oncology. BioCryst leverages computational biology and medicinal chemistry to advance its targeted therapeutic candidates.